Plasma levels of soluble Fas during treatment of chronic hepatitis C patients with interferon alpha [2]

Journal of Hepatology

Volumn 31, Issue 3, 1999, Pages 575-

  Kaser, Arthur ^a   Vogel, Wolfgang ^a   Tilg, Herbert ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; RECEPTOR; RECOMBINANT ALPHA2B INTERFERON;

CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEPATITIS C; HUMAN; LETTER; LIGAND BINDING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0033198320     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80056-7     Document Type: Letter

References (11)

1. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 19:1994;1354-1359.
2. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 182:1995;1223-1230.
3. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
4. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 3:1997;409-413.
5. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology. 229:1997;68-76.
6. Seino K-I, Kayagaki N, Takeda K, Fukao K, Okumura K, Yagita H. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology. 113:1997;1315-1322.
7. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
8. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 154:1995;2706-2713.
9. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol. 29:1998;517-523.
10. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med. 2:1996;317-322.
11. Kaser A, Nagata S, Tilg H. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine. 1999;. in press.